Target: CD40.
Clone: FGK4.5.
Specificity: Anti-CD40 In Vivo Antibody - Ultra Low Endotoxin (FGK4.5) recognizes an epitope on Mouse CD40.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: B cells, basal epithelial cells, macrophages, follicular dendritic cells, and endothelial cells.
Background: CD40, also known as TNFSF5, is a type I transmembrane protein and member of the TNF receptor family. The binding of CD40L (CD154) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 is expressed on B cells, dendritic cells, monocytes, thymic epithelial cells and, at low levels, on T cells. Signaling though CD40 plays an important role in the proliferation and differentiation of B cells and is critical for immunoglobulin (Ig) class switching. The membrane-anchored CD40L is expressed almost exclusively on activated CD4+ T lymphocytes. Failure to express CD40L leads to "immunodeficiency with hyper-IgM", a disease characterized by failure to produce IgG, IgA and IgE. Some of the early intracellular signaling by the CD4-CD40L system includes the association of the CD40 with TRAFs and the activation of various kinases (4). Adaptor protein TNFR2 interacts with this receptor and serves as a mediator of the signal transduction. The interaction of CD4-CD40L is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis.
Immunogen: Recombinant Mouse CD40 Fusion Protein.
Concentration: > 2.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >98% by SDS-PAGE and HPLC.
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 1%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.